Genomic Testing Results and Treatment Implications
Introduction to Genomic Test Results
- Your genomic testing shows a TERT promoter mutation, microsatellite stable (MSS) status, and low tumor mutational burden (TMB of 4.7 mutations/Mb), which indicates your tumor is unlikely to respond to standard immunotherapy but may have specific treatment implications depending on your cancer type, as recommended by the American Academy of Dermatology and the National Comprehensive Cancer Network 1, 2
TERT Promoter Mutation
- TERT promoter mutations regulate telomerase activity, which is highly associated with cancer development and progression, according to research published in Liver International 3
- TERT mutations are found in approximately 36% of HBV-related hepatocellular carcinoma cases and are considered a driver of carcinogenesis, as reported in Liver International 3
- In melanoma, TERT promoter mutations are under investigation for diagnostic and prognostic value, though routine testing is not yet recommended outside of clinical trials, as stated by the American Academy of Dermatology 1
Microsatellite Stable (MSS) Status and Immunotherapy
- MSS tumors typically do not respond well to immune checkpoint inhibitors (anti-PD-1/PD-L1 therapies), as indicated by the National Comprehensive Cancer Network 2
- TMB below 10 mutations/Mb is considered low and predicts poor response to immunotherapy, according to the National Comprehensive Cancer Network 2
- The FDA-approved threshold for TMB-high is ≥10 mutations/Mb, and your result of 4.7 is well below this cutoff, as reported by the National Comprehensive Cancer Network 2
Treatment Approach
- Standard immune checkpoint inhibitors (pembrolizumab, nivolumab) are NOT recommended based on your MSS status and low TMB, as advised by the National Comprehensive Cancer Network 2
- Your treatment should focus on conventional therapies appropriate for your specific cancer type (surgery, chemotherapy, radiation) rather than immunotherapy, as recommended by the National Comprehensive Cancer Network 2
- The TERT mutation alone does not currently have FDA-approved targeted therapies available, as reported in Liver International and the Journal of the American Academy of Dermatology 3, 1
Next Steps and Clinical Trials
- Discuss with your oncologist whether additional molecular testing might identify other actionable targets (such as NTRK fusions, MET fusions, FGFR alterations, or RET fusions), as suggested by the Annals of Oncology 4
- Consider enrollment in clinical trials, particularly those investigating novel therapies for tumors with TERT mutations, as recommended by the Annals of Oncology 4
- Ensure your case is reviewed by a molecular tumor board if available at your institution, as complex genomic profiles benefit from multidisciplinary expertise, as advised by the Annals of Oncology 4